Login or sign up
For business

Bioassets development corporation

3.9· 10 reviews
Average ratingAverage
3.9/ 5

Based on 10 reviews

530%
430%
340%
20%
10%
Mariano Ravinale
Reviews 1

I have had a mixed experience with Bioassets Development Corporation. While their customer service was excellent, I found their products to be average in quality. The prices were reasonable though, which was a plus. Overall, I would say it's an average company.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Bioassets development corporation

BioAssets Development Corporation, a biopharmaceutical company, develops spine indications for biologic drugs. It focuses on the development of a tumor necrosis factor alpha (TNF) inhibitor therapy to treat the underlying cause of pain in sciatica. It markets tumor necrosis factor alpha (TNF) inhibitors, which include monoclonal antibodies, infliximab or adalimumab, TNF-receptor fusion protein etanercept, and biologic drugs for the treatment of inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company’s lead program also tests the potential of TNF inhibitors to treat pain and prevent nerve damage in patients with spinal disorders by treating the neuro-inflammatory disease mechanism. BioAssets Development Corporation was founded in 2005 and is based in Wellesley, Massachusetts. As of November 19, 2010, BioAssets Development Corporation operates as a subsidiary of Cephalon Inc.

Address
888 worcester street
Categories
Biotechnology